RT Journal Article
SR Electronic
T1 “All of the things to everyone everywhere”: A mixed methods analysis of community perspectives on equitable access to monoclonal antibody treatment for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.22.22279097
DO 10.1101/2022.08.22.22279097
A1 Kwan, Bethany M.
A1 Sobczak, Chelsea
A1 Gorman, Carol
A1 Roberts, Samantha
A1 Owen, Vanessa
A1 Wynia, Matthew K.
A1 Ginde, Adit A.
A1 Pena-Jackson, Griselda
A1 Ziegler, Owen
A1 DeCamp, Lisa Ross
YR 2022
UL http://medrxiv.org/content/early/2022/08/23/2022.08.22.22279097.abstract
AB Background Neutralizing monoclonal antibody (mAb) treatment for COVID-19 prevents hospitalization and death but is underused, especially in racial/ethnic minority and rural populations. The study assessed mAbs community awareness and opportunities for improving equitable mAb access.Methods A concurrent mixed methods study including surveys and focus groups with adults with high-risk conditions or their proxy decision-makers. Surveys and focus group guides addressed diffusion of innovation theory factors. Descriptive statistics and Fisher’s exact method was used to report and compare survey findings by race and ethnicity. Rapid qualitative methods were used for focus group analysis.Results Surveys from 515 individuals (460 English, 54 Spanish, 1 Amharic), and 8 focus groups (6 English, 2 Spanish) with 69 diverse participants, all completed between June 2021 and January 2022. Most survey respondents (75%) had heard little or nothing about mAbs, but 95% would consider getting mAb treatment. Hispanic/Latino and Non-Hispanic People of Color (POC) reported less awareness, greater concern about an intravenous infusion, and less trust in mAb safety and effectiveness than White, Non-Hispanic respondents. Focus group themes included little awareness but high interest in mAb treatment and concerns about cost and access, especially for those facing access barriers such as lacking an established source of care and travel from rural communities. Focus groups revealed preferences for broad-reaching but tailored messaging strategies using multiple media and trusted community leaders.Conclusions Despite unfamiliarity with mAb treatment, most respondents were willing to consider receiving mAbs or recommend mAbs to others. While mAb messaging should have broad reach “to everyone everywhere,” racial and geographic disparities in levels of awareness and trust about mAbs underscore the need for tailored messaging to promote equitable access. Care processes should address patient-level mAb barriers, such as transportation, insurance, or primary care access. COVID-19 treatment dissemination strategies should promote health equity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis publication was supported by grants from the National Institutes of Health (NIH https://nih.gov/)/National Center for Advancing Translational Sciences (NCATS https://ncats.nih.gov/) Colorado CTSA Grant Number UL1-TR002535-03 (PI: Ronald Sokol) and 3UL1TR002535-03S3 (MPI: Ronald Sokol and Adit Ginde). Its contents are the authors’ sole responsibility and do not necessarily represent official NIH views. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved as exempt human subjects research by the Colorado Multiple Institutional Review Board (COMIRB Protocol #21-2747). The research was conducted in accordance with universal ethical principles. All participants provided written informed consent using an information consent process embedded in the survey and focus group procedures.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files